Ipragliflozin L-Proline - CAS:951382-34-6

您当前的位置：

Ipragliflozin L-Proline (Synonyms:伊格列净L-脯氨酸)

目录号 : KG10587 CAS No. : 951382-34-6 纯度 : 98%

Data Sheet SDS 产品使用指南

Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. IC50 value: 2.8 nM (SGLT2). Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases. Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice . Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance .

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock
50mg		In-stock
100mg		In-stock
200mg		In-stock
500mg		In-stock
10 mM * 1 mL in DMSO		In-stock

查看所有商品（2）

加入购物车大包装询价

Other Forms of Rapamycin:

Empagliflozin-d4 In-stock
Ertugliflozin-d5 In-stock
Sergliflozin etabonate In-stock
Picraline In-stock
Ipragliflozin L-Proline In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Ipragliflozin L-Proline is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

体外研究

Ipragliflozin L-Proline potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases.

体内研究

Ipragliflozin L-Proline shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance.

分子式

C₂₆H₃₀FNO₇S

分子量

519.58

CAS号

951382-34-6

中文名称

依格列净脯氨酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 20 mg/mL (38.49 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9246 mL	9.6232 mL	19.2463 mL
5 mM	0.3849 mL	1.9246 mL	3.8493 mL
10 mM	0.1925 mL	0.9623 mL	1.9246 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂：10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2 mg/mL (3.85 mM); Clear solution

此方案可获得 ≥ 2 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂：10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2 mg/mL (3.85 mM); Clear solution

此方案可获得 ≥ 2 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。